Prognosis comparison in chronic kidney disease stages 4-5 patients with low parathyroid hormone level due to different causes.

What Was Tested

Researchers studied Parathyroid Hormone (PTH 1-84) in this observational study publication.

Existing studies have focused on secondary hyperparathyroidism with elevated PTH in CKD, but survival outcomes of CKD patients with low PTH remain underexplored.

Who Took Part

According to the abstract, 5 patients were involved.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

This multicenter retrospective cohort study included CKD stages 4-5 patients with PTH < 150 pg/mL from the China Renal Data System, categorized into parathyroidectomy (PTX), Drug, and Unknown Causes (UC) groups based on low PTH etiology.

How the Study Was Run

In design terms this was a multicenter study.

More than one site took part, so the patients came from several places.

Covariates were selected by univariate or LASSO regression.

What Was Measured

Existing studies have focused on secondary hyperparathyroidism with elevated PTH in CKD, but survival outcomes of CKD patients with low PTH remain underexplored.

Topics PubMed links to this paper include China, Cohort Studies, Hyperparathyroidism, Secondary, Parathyroid Hormone, Parathyroidectomy, Prognosis and Renal Insufficiency, Chronic.

Author keywords: Chronic kidney disease, Cohort study, Etiology and Low parathyroid hormone.

What This Means in Plain Language

The paper is a multicenter study of Parathyroid Hormone (PTH 1-84) in 5 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (BMC nephrology), a journal based in England.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.